MILFORD, Massachusetts, March 3, 2020 -- With the rapid global spread of the SARS-CoV-2 virus and the urgent need for reliable diagnostic solutions, LGC’s SeraCare Life Sciences is expanding production of their novel COVID-19 reference materials to include high titer stocks that serve as a valuable tool for diagnostic manufacturers.
Michael Sweatt, Executive Vice President and General Manager, LGC Diagnostics BU, stated: “As a leading provider to the in vitro diagnostic industry, we are keenly aware of the important role that reliable reference materials play in the development of accurate diagnostic tests. Offering our AccuPlex COVID-19 solution in a high titer format enables diagnostic manufacturers to accelerate development efforts through use of concentrated, lot-specific reference material to complete their assay validation activities. Our dedicated team of scientists are expediting production of these stocks, and we anticipate availability in the coming week.”
AccuPlex reference materials, while mimicking wild-type pathogenic viruses, are safe, non-infectious, and replication-deficient. They serve as true, full-process, quality control solutions that challenge the entire diagnostic workflow, making them a valuable alternative to infectious materials.
Notes for editors
About LGC Clinical Diagnostics
LGC’s Clinical Diagnostic Business Unit exists within the LGC’s Standards Division and is comprised of two operating entities - SeraCare Life Sciences and Maine Standards Company. We are in vitro diagnostic (IVD) manufacturers of clinical diagnostic quality solutions to the extended life science industry.
Our 225+ employees operate FDA-registered and ISO 13485-accredited facilities in Maine, Massachusetts and Maryland and support diagnostic professionals in laboratories across the globe. We partner with IVD developers, pharmaceutical, CRO and academic institutions to share our expertise and resources in clinical chemistry, immunochemistry, serology, molecular diagnostics and clinical genomics.
We are committed to improving patient healthcare by offering products and services that support accurate and reliable diagnostic results.
LGC is an international leader in the extended life sciences sector, including human healthcare, agri-food & the environment. LGC provides a comprehensive range of reference materials, proficiency testing schemes, and genomics reagents, as well as research and measurement services. Its scientific tools and solutions enable organizations to advance research, develop new products and form an essential part of their quality and compliance procedures.
LGC’s 3,150 employees include internationally recognized scientists who are experts in their field. Headquartered in London, it operates out of 19 countries worldwide and is extensively accredited to quality standards such as GMP, GLP, ISO 13485, ISO 17034, ISO 17043, ISO/IEC 17025 and ISO 9001.